USA flag logo/image

An Official Website of the United States Government

CODA Assembly of Mutant Genes

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
75888
Program Year/Program:
2009 / STTR
Agency Tracking Number:
AI066758
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
VERDEZYNE, INC.
VERDEZYNE, INC. 2715 LOKER AVE W CARLSBAD, CA 92010 6601
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2009
Title: CODA Assembly of Mutant Genes
Agency: HHS
Contract: 2R42AI066758-02A2
Award Amount: $1,685,628.00
 

Abstract:

DESCRIPTION (provided by applicant): The general goal of this proposal is to assemble directed mutant gene sets quickly, cheaply, easily, and reliably. Mutant gene sets can share sub-assemblies, yielding savings of time, cost, and effort not possible if de signed and assembled all as single genes. The approach is to build upon experience gained in Phase I, to extend and generalize methods of DNA design and assembly, to carry out work plans for each major subsystem, and to validate the resulting system in the wet-lab. Innovation lies in applying computational optimization to mutant sequence assembly, in bringing cluster computing and thermodynamics to the wet-lab, in the integration of different methods, and in the general approach taken. The significance is a method for rapidly, inexpensively, and efficiently constructing mutant gene sets of biomedical importance. We will provide the scientific and medical communities with the ability to perform rapid, inexpensive, and accurate mutational studies of any protei n(s), using a scaffold based on synthetic genes computationally optimized for DNA self-assembly and for expression and translation in an in vitro or in vivo system of choice. This capability will be immediately and directly useful to biomedical researchers , and serve as a platform for protein and metabolic engineering. Mutational studies are one of the primary methods used by biomedical researchers to study and modify protein structure and function. Mutations of a parental gene are the main route to improve d protein expression and function in biopharmaceuticals and industrial enzymes. Function follows sequence. For many reasons, mutant gene sets are important life science research tools. The computational goal of the project is to demonstrate that directed y et complex libraries can be designed and built using this technology. The biological goals have been chosen for their biomedical significance, because integrase is an important retroviral drug target and its understanding is a major medical goal: (1) to fi nd active soluble integrases (IN) for HIV and Ty3 that might lead to crystal structure(s) of active IN(s); (2) to understand the structural basis of retroviral integration and position specific retrovirus- like integration; and (3) to derive chimeric prote ins for position-specific retrovirus vectors, as the position-specific insertion of Ty3 IN might lead to better gene therapy vectors. PUBLIC HEALTH RELEVANCE: The general goal of this proposal is to provide the scientific and medical communities wi th directed mutant gene sets quickly, cheaply, easily, and reliably. Mutational studies are one of the primary methods used by biomedical researchers to study and modify protein structure and function. Mutations of a parental gene are the main route to imp roved protein expression and function in biopharmaceuticals and industrial enzymes.

Principal Investigator:

Shepin Hung
9496751150
SHUNG@CODAGENOMICS.COM

Business Contact:

Steve Jackson
shung@verdezyne.com
Small Business Information at Submission:

VERDEZYNE, INC.
VERDEZYNE, INC. 2715 LOKER AVE W CARLSBAD, CA 92010

EIN/Tax ID: 171098273
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
UNIVERSITY OF CALIFORNIA IRVINE
UNIVERSITY OF CALIFORNIA IRVINE
IRVINE, CA 92697 7600
RI Type: Nonprofit college or university